Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies (original) (raw)

• Ballatore, C., Lee, V. M. Y. & Trojanowski, J. Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Rev. Neurosci. 8, 663–672 (2007).
  CAS Google Scholar
• Lee, V. M. Y., Goedert, M. & Trojanowski, J. Q. Neurodegenerative tauopathies. Ann. Rev. Neurosci. 24, 1121–1159 (2001).
  CAS PubMed Google Scholar
• Kidd, M. Paired helical filaments in electron microscopy of alzheimers disease. Nature 197, 192–193 (1963). The first description of PHFs in Alzheimer's disease neurofibrillary tangles at the electron microscope level.
  CAS PubMed Google Scholar
• Arriagada, P. V., Growdon, J. H., Hedleywhyte, E. T. & Hyman, B. T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimers disease. Neurology 42, 631–639 (1992). This study showed that tangles, not plaques, correlate with dementia severity in Alzheimer's disease.
  CAS PubMed Google Scholar
• Wilcock, G. K. & Esiri, M. M. Plaques, tangles and dementia — a quantitative study. J. Neurological. Sci. 56, 343–356 (1982).
  CAS Google Scholar
• GomezIsla, T. et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41, 17–24 (1997).
  CAS Google Scholar
• George-Hyslop, P. H. & Petit, A. Molecular biology and genetics of Alzheimer's disease. C. R. Biol. 328, 119–130 (2005).
  Google Scholar
• Selkoe, D. J. & Schenk, D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Ann. Rev. Pharmacol. Toxicol. 43, 545–584 (2003).
  CAS Google Scholar
• Goedert, M. Tau gene mutations and their effects. Mov. Disord. 20, S45–S52 (2005).
  PubMed Google Scholar
• Goedert, M. & Jakes, R. Mutations causing neurodegenerative tauopathies. Biochim. Biophys. Acta 1739, 240–250 (2005). A good review of tau mutations that are associated with neurodegenerative disease.
  CAS PubMed Google Scholar
• Brandt, R., Hundelt, M. & Shahani, N. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim. Biophys. Acta 1739, 331–354 (2005).
  CAS PubMed Google Scholar
• Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353–356 (2002).
  CAS PubMed Google Scholar
• Drechsel, D. N., Hyman, A. A., Cobb, M. H. & Kirschner, M. W. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 3, 1141–1154 (1992). One of the earliest studies to define tau functions in microtubule assembly and stability.
  CAS PubMed PubMed Central Google Scholar
• Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E. M. & Mandelkow, E. Domains of tau-protein and interactions with microtubules. Biochemistry 33, 9511–9522 (1994). This study defined domains in tau that interact with microtubules.
  CAS PubMed Google Scholar
• Binder, L. I., Frankfurter, A. & Rebhun, L. I. The distribution of tau in the mammalian central nervous system. J. Cell Biol. 101, 1371–1378 (1985). The first description of the distribution of tau in neurons.
  CAS PubMed Google Scholar
• Andreadis, A., Brown, W. M. & Kosik, K. S. Structure and novel exons of the human-tau gene. Biochemistry 31, 10626–10633 (1992).
  CAS PubMed Google Scholar
• Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D. & Crowther, R. A. Multiple isoforms of human microtubule-associated protein-tau — sequences and localization in neurofibrillary tangles of Alzheimers disease. Neuron 3, 519–526 (1989).
  CAS PubMed Google Scholar
• Panda, D., Samuel, J. C., Massie, M., Feinstein, S. C. & Wilson, L. Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease. Proc. Natl Acad. Sci. USA 100, 9548–9553 (2003).
  CAS PubMed PubMed Central Google Scholar
• Spillantini, M. G. et al. Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc. Natl Acad. Sci. USA 94, 4113–4118 (1997).
  CAS PubMed PubMed Central Google Scholar
• Dayanandan, R. et al. Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett. 446, 228–232 (1999).
  CAS PubMed Google Scholar
• Hasegawa, M., Smith, M. J. & Goedert, M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett. 437, 207–210 (1998).
  CAS PubMed Google Scholar
• Hong, M. et al. Mutation-specific functional impairments in distinct Tau isoforms of hereditary FTDP-17. Science 282, 1914–1917 (1998). This study describes gains and losses of tau functions caused by FTLD17-associated tau gene mutations.
  CAS PubMed Google Scholar
• Barghorn, S. et al. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry 39, 11714–11721 (2000).
  CAS PubMed Google Scholar
• Gamblin, T. C. et al. In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants. Biochemistry 39, 6136–6144 (2000).
  CAS PubMed Google Scholar
• Nacharaju, P. et al. Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. J. Neuropathol. Exp. Neurol. 58, 545 (1999).
  Google Scholar
• Avila, J., Santa-Maria, I., Perez, M., Hernandez, F. & Moreno, F. Tau phosphorylation, aggregation, and cell toxicity. J. Biomed. Biotechnol. 2006, 74539 (2006).
  CAS PubMed PubMed Central Google Scholar
• Avila, J. Tau and tauopathies: tau phosphorylation and tau assembly. FEBS J. 273, 23 (2006).
  Google Scholar
• Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A. & Hof, P. R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev. 33, 95–130 (2000).
  CAS PubMed Google Scholar
• Merrick, S. E., Trojanowski, J. Q. & Lee, V. M. Y. Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons (NT2N cells). J. Neurosci. 17, 5726–5737 (1997).
  CAS PubMed PubMed Central Google Scholar
• Wagner, U., Utton, M., Gallo, J. M. & Miller, C. C. J. Cellular phosphorylation of tau by GSK-3β influences tau binding to microtubules and microtubule organisation. J. Cell Sci. 109, 1537–1543 (1996).
  CAS PubMed Google Scholar
• Alonso, A. D., GrundkeIqbal, I. & Iqbal, K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nature Med. 2, 783–787 (1996).
  CAS PubMed Google Scholar
• Alonso, A. D., GrundkeIqbal, I. & Iqbal, K. Abnormally phosphorylated tau from Alzheimer disease brain depolymerizes microtubules. Neurobiol. Aging 15, S37 (1994).
  Google Scholar
• Necula, M. & Kuret, J. Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J. Biol. Chem. 279, 49694–49703 (2004).
  CAS PubMed Google Scholar
• Kins, S. et al. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J. Biol. Chem. 276, 38193–38200 (2001).
  CAS PubMed Google Scholar
• Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W. & Gong, C. X. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc. Natl Acad. Sci. USA 101, 10804–10809 (2004). This study describes a potential alternative strategy to reduce tau hyperphosphorylation.
  CAS PubMed PubMed Central Google Scholar
• Lefebvre, T. et al. Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins — a role in nuclear localization. Biochim. Biophys. Acta 1619, 167–176 (2003).
  CAS PubMed Google Scholar
• Lee, G. et al. Phosphorylation of tau by fyn: implications for Alzheimer's disease. J. Neurosci. 24, 2304–2312 (2004).
  CAS PubMed PubMed Central Google Scholar
• Gong, C. X., Liu, F., Grundke-Iqbal, I. & Iqbal, K. Post-translational modifications of tau protein in Alzheimer's disease. J. Neural Transm. 112, 813–838 (2005).
  CAS PubMed Google Scholar
• Park, S. Y. & Ferreira, A. The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates β-amyloid-induced neurodegeneration. J. Neurosci. 25, 5365–5375 (2005).
  CAS PubMed PubMed Central Google Scholar
• Gamblin, T. C. et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl Acad. Sci. USA 100, 10032–10037 (2003).
  CAS PubMed PubMed Central Google Scholar
• Chirita, C. N., Necula, M. & Kuret, J. Anionic micelles and vesicles induce tau fibrillization in vitro. J. Biol. Chem. 278, 25644–25650 (2003).
  CAS PubMed Google Scholar
• Wilson, D. M. & Binder, L. I. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am. J. Pathol. 150, 2181–2195 (1997).
  CAS PubMed PubMed Central Google Scholar
• Gauthier, S. et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J. Nutr. Health Aging 13, 550–557 (2009).
  CAS PubMed Google Scholar
• Green, R. C., Schneider, L. S., Hendrix, S., Zavitz, K. & Swabb, E. Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: results from an 18 month multicenter phase 3 trial. Eur. J. Neurol. 15, 412 (2008).
  Google Scholar
• Hempen, B. & Brion, J. P. Reduction of acetylated α-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 55, 964–972 (1996).
  CAS PubMed Google Scholar
• Bendiske, J., Caba, E., Brown, Q. B. & Bahr, B. A. Intracellular deposition, microtubule destabilization, and transport failure: an “early” pathogenic cascade leading to synaptic decline. J. Neuropathol. Exp. Neurol. 61, 640–650 (2002).
  CAS PubMed Google Scholar
• Ishihara, T. et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24, 751–762 (1999).
  CAS PubMed Google Scholar
• Cash, A. D. et al. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am. J. Pathol. 162, 1623–1627 (2003).
  CAS PubMed PubMed Central Google Scholar
• Yuan, A., Kumar, A., Peterhoff, C., Duff, K. & Nixon, R. A. Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J. Neurosci. 28, 1682–1687 (2008).
  CAS PubMed PubMed Central Google Scholar
• Roberson, E. D. et al. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316, 750–754 (2007).
  CAS PubMed Google Scholar
• Harada, A. et al. Altered microtubule organization in small-caliber axons of mice lacking tau protein. Nature 369, 488–491 (1994).
  CAS PubMed Google Scholar
• Dawson, H. N. et al. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J. Cell Sci. 114, 1179–1187 (2001).
  CAS PubMed Google Scholar
• Ikegami, S., Harada, A. & Hirokawa, N. Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neurosci. Lett. 279, 129–132 (2000).
  CAS PubMed Google Scholar
• Zhang, B. et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl Acad. Sci. USA 102, 227–231 (2005). This study provided evidence that a small-molecule microtubule stabilizer could compensate for loss of tau function.
  CAS PubMed Google Scholar
• Gozes, I. & Divinski, I. The femtomolar-acting NAP interacts with microtubules: novel aspects of astrocyte protection. J. Alzheimers Dis. 6, S37–S41 (2004).
  CAS PubMed Google Scholar
• Matsuoka, Y. et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J. Mol. Neurosci. 31, 165–170 (2007).
  CAS PubMed Google Scholar
• Matsuoka, Y. et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 325, 146–153 (2008). A proof-of-concept study of NAP, the first putative microtubule-stabilizing drug to enter a clinical trial, in a transgenic mouse model of Alzheimer's disease.
  CAS PubMed Google Scholar
• Ballatore, C. et al. Paclitaxel C-10 carbamates: potential candidates for the treatment of neurodegenerative tauopathies. Bioorg. Med. Chem. Lett. 17, 3642–3646 (2007).
  CAS PubMed PubMed Central Google Scholar
• Fellner, S. et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Invest. 110, 1309–1318 (2002).
  CAS PubMed PubMed Central Google Scholar
• Matsuo, E. S. et al. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimers disease paired helical filament tau. Neuron 13, 989–1002 (1994). This study showed that nearly all phosphorylation sites in PHFtau also exist in normal tau isolated from rapidly processed human cortical biopsies, establishing that the abnormal phosphorylation in PHFtau is defined by quantitative rather than qualitative differences to normal tau.
  CAS PubMed Google Scholar
• Hasegawa, M. et al. Protein sequence and mass spectrometric analyses of tau in the Alzheimers disease brain. J. Biol. Chem. 267, 17047–17054 (1992). This paper describes extensively mapped PHFtau phosphorylation sites.
  CAS PubMed Google Scholar
• Hanger, D. P., Anderton, B. H. & Noble, W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15, 112–119 (2009).
  CAS PubMed Google Scholar
• Sengupta, A. et al. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch. Biochem. Biophys. 357, 299–309 (1998).
  CAS PubMed Google Scholar
• Alonso, A. D., Mederlyova, A., Novak, M., Grundke-Iqbal, I. & Iqbal, K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J. Biol. Chem. 279, 34873–34881 (2004).
  Google Scholar
• Schneider, A., Biernat, J., von Bergen, M., Mandelkow, E. & Mandelkow, E. M. Phosphorylation that detaches tau from microtubules S262 and S214 protects it against aggregation into Alzheimer paired helical filaments. J. Neurochem. 73, S26 (1999).
  Google Scholar
• Ghoreschi, K., Laurence, A. & O'Shea, J. J. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nature Immunol. 10, 356–360 (2009).
  CAS Google Scholar
• Mazanetz, M. P. & Fischer, P. M. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nature Rev. Drug Discov. 6, 464–479 (2007). An excellent review on medicinal chemistry efforts to develop tau kinase inhibitors.
  CAS Google Scholar
• Gong, C. X. & Iqbal, K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr. Med. Chem. 15, 2321–2328 (2008).
  CAS PubMed PubMed Central Google Scholar
• Imahori, K. & Uchida, T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J. Biochem. 121, 179–188 (1997).
  CAS PubMed Google Scholar
• Pei, J. J. et al. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56, 70–78 (1997).
  CAS PubMed Google Scholar
• Lucas, J. J. et al. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. 20, 27–39 (2001).
  CAS PubMed PubMed Central Google Scholar
• Hernandez, F., Borrell, J., Guaza, C., Avila, J. & Lucas, J. J. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3β in the brain but do not form tau filaments. J. Neurochem. 83, 1529–1533 (2002).
  CAS PubMed Google Scholar
• Lee, K. Y. et al. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci. Res. 34, 21–29 (1999).
  CAS PubMed Google Scholar
• Tseng, H. C., Zhou, Y., Shen, Y. & Tsai, L. H. A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett. 523, 58–62 (2002).
  CAS PubMed Google Scholar
• Yamaguchi, H. et al. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK)I glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. 92, 232–241 (1996).
  CAS PubMed Google Scholar
• Augustinack, J. C., Sanders, J. L., Tsai, L. H. & Hyman, B. T. Colocalization and fluorescence resonance energy transfer between cdk5 and AT8 suggests a close association in pre-neurofibrillary tangles and neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 61, 557–564 (2002).
  CAS PubMed Google Scholar
• Pei, J. J. et al. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res. 797, 267–277 (1998).
  CAS PubMed Google Scholar
• Noble, W. et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555–565 (2003).
  CAS PubMed Google Scholar
• Cruz, J. C. et al. P25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid β in vivo. J. Neurosci. 26, 10536–10541 (2006).
  CAS PubMed PubMed Central Google Scholar
• Phiel, C. J., Wilson, C. A., Lee, V. M. Y. & Klein, P. S. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 423, 435–439 (2003).
  CAS PubMed Google Scholar
• Aplin, A. E., Jacobsen, J. S., Anderton, B. H. & Gallo, J. M. Effect of increased glycogen synthase kinase-3 activity upon the maturation of the amyloid precursor protein in transfected cells. Neuroreport 8, 639–643 (1997).
  CAS PubMed Google Scholar
• Rockenstein, E. et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3β signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J. Neurosci. 27, 1981–1991 (2007).
  CAS PubMed PubMed Central Google Scholar
• Wen, Y. et al. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3β mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J. Neurosci. 28, 2624–2632 (2008).
  CAS PubMed PubMed Central Google Scholar
• Drewes, G., Ebneth, A., Preuss, U., Mandelkow, E. M. & Mandelkow, E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 89, 297–308 (1997). This study defined MARK as an important family of kinases that phosphorylates tau.
  CAS PubMed Google Scholar
• Chin, J. Y. et al. Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy transfer study. J. Neuropathol. Exp. Neurol. 59, 966–971 (2000).
  CAS PubMed Google Scholar
• Nishimura, I., Yang, Y. F. & Lu, B. W. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116, 671–682 (2004).
  CAS PubMed Google Scholar
• Medina, M. & Castro, A. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr. Opin. Drug Discov. Dev. 11, 533–543 (2008).
  CAS Google Scholar
• Dhavan, R. & Tsai, L. H. A decade of CDK5. Nature Rev. Mol. Cell Biol. 2, 749–759 (2001).
  CAS Google Scholar
• Biernat, J. et al. Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol. Biol. Cell 13, 4013–4028 (2002).
  CAS PubMed PubMed Central Google Scholar
• Mandelkow, E. M., Thies, E., Trinczek, B., Biernat, J. & Mandelkow, E. MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J. Cell Biol. 167, 99–110 (2004).
  CAS PubMed PubMed Central Google Scholar
• Churcher, I. Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr. Top. Med. Chem. 6, 579–595 (2006).
  CAS PubMed Google Scholar
• Lee, V. M. Y., Kenyon, T. K. & Trojanowski, J. Q. Transgenic animal models of tauopathies. Biochim. Biophys. Acta 1739, 251–259 (2005).
  CAS PubMed Google Scholar
• Noble, W. et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA 102, 6990–6995 (2005).
  CAS PubMed PubMed Central Google Scholar
• Perez, M., Hernandez, F., Lim, F., Diaz-Nido, J. & Avila, J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J. Alzheimers Dis. 5, 301–308 (2003).
  CAS PubMed Google Scholar
• Nakashima, H. et al. Effect of chronic lithium treatment on an animal model of tauopathies. Neurobiol. Aging 25, S595 (2004).
  Google Scholar
• Engel, T., Goni-Oliver, P., Lucas, J. J., Avila, J. & Hernandez, F. Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J. Neurochem. 99, 1445–1455 (2006).
  CAS PubMed Google Scholar
• Caccamo, A., Oddo, S., Tran, L. X. & LaFerla, F. M. Lithium reduces tau phosphorylation but not Aβ or working memory deficits in a transgenic model with both plaques and tangles. Am. J. Pathol. 170, 1669–1675 (2007).
  CAS PubMed PubMed Central Google Scholar
• Hampel, H. et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled multicenter 10-week study. J. Clin. Psychiatry 70, 922–931 (2009). This paper describes a clinical trial, albeit a small one, that failed to demonstrate significant ameliorative effects of lithium therapy.
  CAS PubMed Google Scholar
• Le Corre, S. et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc. Natl Acad. Sci. USA 103, 9673–9678 (2006).
  CAS PubMed PubMed Central Google Scholar
• Selenica, M. L. et al. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Brit. J. Pharmacol. 152, 959–979 (2007).
  CAS Google Scholar
• Fischer, P. M. Turning down tau phosphorylation. Nature Chem. Biol. 4, 448–449 (2008).
  CAS Google Scholar
• Yuzwa, S. A. et al. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nature Chem. Biol. 4, 483–490 (2008).
  CAS Google Scholar
• Hasegawa, M., Crowther, R. A., Jakes, B. & Goedert, M. Alzheimer-like changes in microtubule-associated protein tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation. J. Biol. Chem. 272, 33118–33124 (1997).
  CAS PubMed Google Scholar
• Wischik, C. M., Edwards, P. C., Lai, R. Y. K., Roth, M. & Harrington, C. R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl Acad. Sci. USA 93, 11213–11218 (1996). One of the earliest in vitro studies of compounds that inhibit tau aggregation.
  CAS PubMed PubMed Central Google Scholar
• Staff, R. T. et al. Tau aggregation inhibitor (TAI) therapy with rember arrests the trajectory of rCBF decline in brain regions affected by tau pathology in mild to moderate Alzheimer's disease. Alzheimers Dement. 4, T775 (2008).
  Google Scholar
• Chirita, C., Necula, M. & Kuret, J. Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 43, 2879–2887 (2004).
  CAS PubMed Google Scholar
• Congdon, E. E., Necula, M., Blackstone, R. D. & Kuret, J. Potency of a tar fibrillization inhibitor is influenced by its aggregation state. Arch. Biochem. Biophys. 465, 127–135 (2007).
  CAS PubMed PubMed Central Google Scholar
• Pickhardt, M. et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J. Biol. Chem. 280, 3628–3635 (2005). This study describes the screening of a large chemical library of inhibitors of tau fibril formation.
  CAS PubMed Google Scholar
• Khlistunova, I. et al. Inducible expression of tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J. Biol. Chem. 281, 1205–1214 (2006).
  CAS PubMed Google Scholar
• Larbig, G., Pickhardt, M., Lloyd, D. G., Schmidt, B. & Mandelkow, E. Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: a ligand based approach results in successful scaffold hopping. Curr. Alzheimer Res. 4, 315–323 (2007).
  CAS PubMed Google Scholar
• Pickhardt, M. et al. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 46, 10016–10023 (2007).
  CAS PubMed Google Scholar
• Bulic, B. et al. Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew. Chem. Int. Ed. Engl. 46, 9215–9219 (2007).
  PubMed Google Scholar
• Taniguchi, S. et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280, 7614–7623 (2005).
  CAS PubMed Google Scholar
• Crowe, A., Ballatore, C., Hyde, E., Trojanowski, J. Q. & Lee, V. M. Y. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem. Biophys. Res. Commun. 358, 1–6 (2007).
  CAS PubMed PubMed Central Google Scholar
• Crowe, A. et al. The identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48, 7732–7745 (2009).
  CAS PubMed Google Scholar
• Feng, B. Y. et al. Small-molecule aggregates inhibit amyloid polymerization. Nature Chem. Biol. 4, 197–199 (2008).
  CAS Google Scholar
• Congdon, E. E. et al. Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants. J. Biol. Chem. 283, 13806–13816 (2008).
  CAS PubMed PubMed Central Google Scholar
• Drubin, D. G., Feinsteni, S. C., Shooter, E. M. & Kirschner, M. W. Nerve growth factor-induced neurite outgrowth in PC12 cells involves the coordinate induction of microtubule assembly and assembly-promoting factors. J. Cell Biol. 101, 1799–1807 (1985).
  CAS PubMed Google Scholar
• Brunden, K., Trojanowski, J. Q. & Lee, V. M. Y. Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J. Alzheimers Dis. 14, 393–399 (2008).
  PubMed PubMed Central Google Scholar
• Ravikumar, B., Sarkar, S., Berger, Z. & Rubinsztein, D. C. The roles of the ubiquitin-proteasome and autophagy-lysosome pathways in Huntington's disease and related conditions. Clin. Neurosci. Res. 3, 141–148 (2003).
  CAS Google Scholar
• Nixon, R. A. Autophagy in neurodegenerative disease: friend, foe or turncoat? Trends Neurosci. 29, 528–535 (2006).
  CAS PubMed Google Scholar
• Nixon, R. A. et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 64, 113–122 (2005).
  PubMed Google Scholar
• Hamos, J. E. et al. Expression of heat-shock proteins in Alzheimers disease. Neurology 41, 345–350 (1991).
  CAS PubMed Google Scholar
• Perez, N. et al. Increased synthesis and accumulation of heat-shock 70 proteins in Alzheimers disease. Mol. Brain Res. 11, 249–254 (1991).
  CAS PubMed Google Scholar
• Keck, S., Nitsch, R., Grune, T. & Ullrich, O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J. Neurochem. 85, 115–122 (2003).
  CAS PubMed Google Scholar
• Keller, J. N., Hanni, K. B. & Markesbery, W. R. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75, 436–439 (2000).
  CAS PubMed Google Scholar
• Dickey, C. A. et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 117, 648–658 (2007). This study proposed a mechanism for HSP90 involvement in the degradation of phosphorylated tau.
  CAS PubMed PubMed Central Google Scholar
• Zhang, H. & Burrows, F. Targeting multiple signal transduction pathways through inhibition of HSP90. J. Mol. Med. 82, 488–499 (2004).
  CAS PubMed Google Scholar
• Dickey, C. A. et al. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. Faseb J. 20, 753–755 (2006).
  CAS PubMed Google Scholar
• Luo, W. J. et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc. Natl Acad. Sci. USA 104, 9511–9516 (2007).
  CAS PubMed PubMed Central Google Scholar
• Kamal, A. et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407–410 (2003).
  CAS PubMed Google Scholar
• Williams, A. et al. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr. Top. Dev. Biol. 76, 89–101 (2006).
  CAS PubMed Google Scholar
• Berger, Z. et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15, 433–442 (2006).
  CAS PubMed Google Scholar
• Hamano, T. et al. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur. J. Neurosci. 27, 1119–1130 (2008).
  PubMed Google Scholar
• Sarkar, S. et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170, 1101–1111 (2005).
  CAS PubMed PubMed Central Google Scholar
• SantaCruz, K. et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476–481 (2005).
  CAS PubMed PubMed Central Google Scholar
• Friedhoff, P., Schneider, A., Mandelkow, E. M. & Mandelkow, E. Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry 37, 10223–10230 (1998).
  CAS PubMed Google Scholar